Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- SARS COV2
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Prospective, randomized, single-blind, controlled trialMasking: Single (Participant)Masking Description: Single-blinded studyPrimary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04344600
- Collaborators
- Eiger BioPharmaceuticals
- Investigators
- Principal Investigator: Mark Sulkowski, MD Johns Hopkins University
Get Well Soon